Quarterly report pursuant to Section 13 or 15(d)

Collaborative Arrangements - Merck Platform Technology Transfer and License Agreement (Details)

v3.20.2
Collaborative Arrangements - Merck Platform Technology Transfer and License Agreement (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Aug. 31, 2015
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Revenue recognized $ 18,385 $ 21,906 $ 48,023 $ 49,808    
Contract with customer, liability 4,056   4,056   $ 2,044  
Merck [Member] | Technology Transfer, Collaboration and License Agreement [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Contingent receivable           $ 15,000
Merck [Member] | Technology Transfer, Collaboration and License Agreement [Member] | Research and Development Revenue [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Revenue recognized $ 1,100 1,100 $ 2,100 4,000    
Merck [Member] | Technology Transfer, Collaboration and License Agreement [Member] | License Fee [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Revenue recognized   $ 100   $ 1,000